LFMD
LifeMD, Inc.
LFMD's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over LFMD overall, supported by stronger fundamentals and lower modeled downside.
LFMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Strong |
LFMD's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LFMD PE Valuation
LFMD has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LFMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect LFMD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LFMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.05 | +$0.11 |
| Q2 2026 | -$0.04 | +$0.16 |
| Q1 2026 | $0.06 | +$0.39 |
| Q4 2025 | $0.27 | +$0.80 |
| Q3 2025 | -$0.16 | +$0.48 |
| Q2 2025 | -$0.20 | +$0.50 |
| Q1 2025 | -$0.33 | +$0.41 |
| Q4 2024 | -$0.53 | +$0.17 |
LFMD lost $0.05 per share over the past year, a smaller loss than the year before, but its loss has widened in each of the last three quarters.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over LFMD on earnings quality, reporting a profit while its opponent remains loss making.
LFMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $44.6M | -26% |
| Q2 2026 | $47.3M | -24% |
| Q1 2026 | $50.2M | -24% |
| Q4 2025 | $7.1M | -89% |
| Q3 2025 | $60.2M | +13% |
| Q2 2025 | $62.2M | +23% |
| Q1 2025 | $65.7M | +49% |
| Q4 2024 | $64.3M | +43% |
LFMD's revenue has slid since its 2025 peak: $45M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | -6.7 points |
| Q2 2026 | -15% | -14 points |
| Q1 2026 | -18% | -22 points |
| Q4 2025 | -88% | -90 points |
| Q3 2025 | -3.3% | +5.5 points |
| Q2 2025 | -1.5% | +11 points |
| Q1 2025 | 3.9% | +18 points |
| Q4 2024 | 1.6% | +6.4 points |
LFMD's operating margin was −10% last quarter, down 6.7 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LFMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LFMD on profitability, with a higher operating margin.
LFMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1M | -$176K |
| Q2 2026 | -$7M | -189% |
| Q1 2026 | $339.4K | -88% |
| Q4 2025 | -$3.4M | -356% |
| Q3 2025 | -$944.4K | -116% |
| Q2 2025 | $7.8M | +101% |
| Q1 2025 | $2.9M | -41% |
| Q4 2024 | $1.3M | -76% |
LFMD's free cash flow was −$11M over the past year, against $11M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over LFMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
LFMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +394K shares |
| 1 year | +4.4% | +2M shares |
| 3 years | +40% | +13.7M shares |
| 5 years | +81% | +21.5M shares |
| Available history | +387% | +38.3M shares |
LFMD has 48M diluted shares, up 4.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2025 | $270,000 |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LFMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LFMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -9.6x | Net Cash |
LFMD has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LFMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.5 | Oversold |
| Stochastic | 10.1 | Oversold |
LFMD's weekly RSI is 27 (oversold) and its Stochastic is 10 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LFMD PE vs Healthcare Sector
| Metric | LFMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LFMD has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LFMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.39 | 31% below |
| 20 week MA | $3.14 | 47% below |
| 50 week MA | $3.54 | 53% below |
| 100 week MA | $5.40 | 69% below |
| 200 week MA | $5.43 | 69% below |
LFMD is in a downtrend: it's below all five of its weekly moving averages, and 69% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LFMD on trend strength, trading above more of its moving averages.
LFMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.65 | $7.84 | +1106% |
| 2021 | $7.84 | $4.32 | -45% |
| 2022 | $4.32 | $2.05 | -53% |
| 2023 | $2.05 | $8.29 | +304% |
| 2024 | $8.29 | $5.22 | -37% |
| 2025 | $5.22 | $3.50 | -33% |
| 2026 YTD | $3.50 | $1.66 | -53% |
LFMD's yearly returns have swung widely, from +1106% in 2020 to −53% in 2022. It's down 53% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LFMD on returns for 2026, with the stronger performance.